United States Gastric Motility Disorder Drugs Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Global Gastric Motility Disorder Drugs Market reached US$54.7 billion in 2024 and is expected to reach US$90.41 billion by 2033, growing at a CAGR of 5.0% during the forecast period 2025-2033, according to DataM intelligence report.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/gastric-motility-disorder-drugs-market?sb

Key Development:

United States: Recent Industry Developments

✅ In March 2026, Vanda Pharmaceuticals continued late-stage development of tradipitant for gastroparesis and related gastric motility disorders after regulatory feedback from the U.S. FDA requesting additional clinical data. The drug targets nausea and vomiting linked to delayed gastric emptying. The program supports development of new therapies for patients with limited treatment options.

✅ In February 2026, Processa Pharmaceuticals advanced PCS-12852 into Phase II clinical trials for moderate-to-severe gastroparesis following regulatory clearance. The drug is designed to improve gastric emptying and reduce symptoms such as bloating and nausea. The development reflects growing focus on next-generation prokinetic therapies.

✅ In January 2026, Neurogastrx expanded research on novel gastroparesis drugs including tradipitant and metopimazine targeting symptoms caused by impaired stomach motility. The pipeline focuses on improving treatment safety compared with older dopamine-based therapies. The initiative strengthens innovation in gastrointestinal motility disorder treatments.

✅ In December 2025, the U.S. FDA approved tradipitant for motion-induced vomiting, supporting broader clinical development of the same drug for gastric motility disorders and gastroparesis. The therapy blocks neurokinin-1 receptors involved in nausea and vomiting pathways. The approval strengthens confidence in its use for additional gastrointestinal indications.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=gastric-motility-disorder-drugs-market

Japan: Recent Industry Developments

✅ In March 2026, Takeda Pharmaceutical continued expansion of its gastrointestinal drug portfolio with ongoing research in advanced therapies targeting acid-related and motility-related digestive disorders. The company is focusing on innovative treatments for chronic gastric conditions requiring long-term management. The strategy supports Japan's leadership in gastrointestinal drug development.

✅ In February 2026, Japanese pharmaceutical companies increased clinical research on prokinetic agents used to treat gastroparesis and functional dyspepsia as demand rises with the aging population. These drugs aim to improve stomach emptying and digestive motility. The research supports development of safer long-term therapies for chronic gastric disorders.

✅ In January 2026, healthcare research programs in Japan expanded use of AI-driven drug discovery platforms to accelerate development of treatments for gastrointestinal motility disorders. The approach helps identify new molecular targets for delayed gastric emptying and related conditions. It supports faster development of precision medicines.

✅ In December 2025, Japanese regulatory authorities approved new pharmaceutical listings including gastrointestinal therapies, supporting continued innovation in digestive disorder treatment. The approvals help improve availability of advanced drugs for chronic stomach and intestinal conditions. The move strengthens Japan's pharmaceutical pipeline for GI diseases.

Key Players:

=> Pfizer Inc., Eisai Co., Ltd., Mallinckrodt, Salvus Pharma, Atmo Biosciences, AdvaCare Pharma, Avenacy, VAIKUNTH CHEMICALS PVT. LTD., Healthy Inc and Bhumi Pharmaceuticals among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gastric-motility-disorder-drugs-market?sb

Key Segments:

By Drug Type

Parasympathomimetics - 14% Share
Used to stimulate gastrointestinal motility and improve digestion, commonly prescribed for motility disorders.

Prokinetic Agents - 20% Share
Leading segment due to high effectiveness in treating gastroparesis, GERD, and other gastrointestinal motility disorders.

Opioid Antagonists - 10% Share
Used to treat opioid-induced constipation and related digestive complications.

Antidiarrheals - 15% Share
Widely used for treating acute and chronic diarrhea associated with gastrointestinal disorders.

Anti-Emetic Drugs - 12% Share
Used to control nausea and vomiting caused by digestive disorders and other medical treatments.

Antibiotics - 13% Share
Prescribed for infections affecting the gastrointestinal tract, including bacterial overgrowth conditions.

Others - 16% Share
Includes antacids, laxatives, and combination therapies used for various digestive disorders.

By Disorder Type

Achalasia - 6% Share
Rare disorder requiring specialized drug therapy to relax esophageal muscles.

Esophageal Spasms - 7% Share
Treated using muscle relaxants and motility-improving drugs.

Heartburn / GERD - 24% Share
Largest segment due to high global prevalence of acid reflux and lifestyle-related digestive issues.

Gastroparesis - 12% Share
Growing demand for prokinetic drugs to improve stomach emptying.

Irritable Bowel Syndrome (IBS) - 18% Share
High demand for antidiarrheals, laxatives, and motility drugs.

Fecal Incontinence - 8% Share
Treated using antidiarrheal and motility-control medications.

Intestinal Pseudo-obstruction - 5% Share
Rare condition requiring specialized drug therapy.

Others - 20% Share
Includes constipation, dyspepsia, and other gastrointestinal disorders.

By Distribution Channel

Hospital Pharmacies - 38% Share
Largest segment due to prescription-based treatment and hospital-administered therapies.

Retail Pharmacies - 42% Share
Leading channel for over-the-counter and prescription digestive disorder medications.

Online Pharmacies - 20% Share
Fastest growing segment due to convenience, home delivery, and rising digital healthcare adoption.

By Region

North America - 33% Share
Dominates the market due to high prevalence of digestive disorders and advanced healthcare infrastructure.

Europe - 25% Share
Strong demand driven by aging population and high diagnosis rates.

Asia Pacific - 27% Share
Fastest growing region due to increasing lifestyle diseases and expanding healthcare access.

Latin America - 8% Share
Growing adoption of gastrointestinal drugs in urban healthcare systems.

Middle East & Africa - 7% Share
Rising demand due to improving healthcare facilities and increasing awareness of digestive health.

FAQ

What is the current size of the Gastric Motility Disorder Drugs Market?

A: In 2024, the Gastric Motility Disorder Drugs Market was valued at US$54.7 billion, reflecting its strong industry presence.

Q2: How large is the Gastric Motility Disorder Drugs Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Gastric Motility Disorder Drugs Market will grow to around US$90.41 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Gastric Motility Disorder Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.0% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.